Marksans Pharma Ltd Q4FY17
Standalone Results Q4FY17: (Rs. in crore)
|EBITDA Margin (%)||7.4|||
|Net Profit (adjusted)||0.57||[88.8]|
Marksans Pharma standalone revenue for the quarter came in at Rs. 54 crore, registering 21.7% yoy decline.
EBITDA for the quarter fell by 42.9% yoy to Rs. 4 crore with a corresponding margin contraction of 273 bps. EBITDA margin for the quarter stood at 7.4%. This margin contraction was driven by 19% yoy increase in employee benefit expenses.
The PAT for the quarter came in at Rs. 0.57 crore, yoy decline of 88.8%. This was backd by 31% yoy increase in finance cost.
Looking at the full year numbers, we see that revenue slided by 40% to reach Rs.215.84 crore while EBITDA fell by 77% to 24.27 crore. Company reported net profit of Rs.12.22 crore, down 83% yoy.
The board has recommended dividend of Rs. 0.05 per share for the face value of Rs. 1 each.
Marksans Pharma Ltd is currently trading at Rs. 42.6, down by 3.75 points or 8.09% from its previous closing of Rs. 46.35 on the BSE.
The scrip opened at Rs. 46.7 and has touched a high and low of Rs. 46.8 and Rs. 42.45 respectively. So far 5691273(NSE+BSE) shares were traded on the counter. The stock is currently trading above its 50 DMA.